Enzalutamide May Represent Novel Therapeutic Option for Triple-Negative Breast Cancer
Enzalutamide may be a viable alternative therapy over cytotoxic chemotherapy for individuals with triple-negative breast cancer, according to a study presented at the 2015 American Society of Clinical Oncology annual meeting.